Giuseppe Tagariello1, Giancarlo Castaman2, Anna Falanga3, Rita Santoro4, Mariasanta Napolitano5, Sergio Storti6, Dino Veneri7, Marco Basso1, Laura Candiotto1, Cristina Tassinari1, Augusto B Federici8, Valerio De Stefano6. 1. Transfusion Service, Haemophilia Centre and Haematology, Castelfranco Veneto Hospital, Castelfranco Veneto, Italy. 2. Centre for Bleeding Disorders, Careggi University Hospital, Florence, Italy. 3. Department of Immunohaematology and Transfusion Medicine and Haemostasis and Thrombosis Centre, Papa Giovanni XXIII Hospital, Bergamo, Italy. 4. Haemophilia Centre, Haemostasis and Thrombosis Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy. 5. Unit of Haematology and Transplantation, University Hospital of Palermo, Palermo, Italy. 6. Department of Haematology, Catholic University, Rome, Italy. 7. Department of Medicine; Department of Medicine; University of Verona; Verona, Italy. 8. Haematology and Transfusion Medicine, "L. Sacco" University Hospital, Department of Oncology and Haematology-Oncology, University of Milan, Milan, Italy.
Abstract
BACKGROUND: Following high-dose chemotherapy/bone marrow transplantation, patients are routinely, prophylactically transfused with platelet concentrates (PC) if they have a platelet count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such transfusions are necessary in clinically stable patients with no bleeding, or whether a therapeutic transfusion strategy could be sufficient and safe, is still debated. MATERIALS AND METHODS: The GIMEMA Haemostasis and Thrombosis Working Party sent a questionnaire to Italian haematology departments to survey several aspects of daily platelet transfusion practice, such as the cut-off platelet count for transfusion, the evaluation of refractoriness and the type of PC administered. RESULTS: The questionnaire was answered by 18 out of 31 centres (58%). A total of 23,162 PC were transfused in 2,396 patients in 2013. The vast majority of centres (95%) transfused PC according to Italian and international guidelines; only a few transfused always at platelet counts ≤20×109/L. The broad agreement on platelet count cut-off for transfusion (≤10×109/L) was not confirmed when the World Health Organization (WHO) bleeding score was considered: only a third of centres (33%) used transfusions as recommended when the bleeding grade was ≥2. Platelet refractoriness was poorly monitored and most centres (89%) evaluated, mostly empirically (67%), response to transfusion only 24 hours later. Thirty percent of centres transfused platelets in asymptomatic refractory patients. DISCUSSION: Although most Italian haematology departments transfuse PC according to Italian and international guidelines, our survey shows that in routine daily practice physicians do not comply closely with the WHO recommendations on platelet transfusions and monitoring platelet refractoriness. This causes excessive platelet transfusions, with a resulting increase of costs and waste of public health resources.
BACKGROUND: Following high-dose chemotherapy/bone marrow transplantation, patients are routinely, prophylactically transfused with platelet concentrates (PC) if they have a platelet count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such transfusions are necessary in clinically stable patients with no bleeding, or whether a therapeutic transfusion strategy could be sufficient and safe, is still debated. MATERIALS AND METHODS: The GIMEMA Haemostasis and Thrombosis Working Party sent a questionnaire to Italian haematology departments to survey several aspects of daily platelet transfusion practice, such as the cut-off platelet count for transfusion, the evaluation of refractoriness and the type of PC administered. RESULTS: The questionnaire was answered by 18 out of 31 centres (58%). A total of 23,162 PC were transfused in 2,396 patients in 2013. The vast majority of centres (95%) transfused PC according to Italian and international guidelines; only a few transfused always at platelet counts ≤20×109/L. The broad agreement on platelet count cut-off for transfusion (≤10×109/L) was not confirmed when the World Health Organization (WHO) bleeding score was considered: only a third of centres (33%) used transfusions as recommended when the bleeding grade was ≥2. Platelet refractoriness was poorly monitored and most centres (89%) evaluated, mostly empirically (67%), response to transfusion only 24 hours later. Thirty percent of centres transfused platelets in asymptomatic refractory patients. DISCUSSION: Although most Italian haematology departments transfuse PC according to Italian and international guidelines, our survey shows that in routine daily practice physicians do not comply closely with the WHO recommendations on platelet transfusions and monitoring platelet refractoriness. This causes excessive platelet transfusions, with a resulting increase of costs and waste of public health resources.
Authors: P Rebulla; G Finazzi; F Marangoni; G Avvisati; L Gugliotta; G Tognoni; T Barbui; F Mandelli; G Sirchia Journal: N Engl J Med Date: 1997-12-25 Impact factor: 91.245
Authors: S Schmitt; V Mailaender; G Egerer; A Leo; S Becker; P Reinhardt; M Wiesneth; H Schrezenmeier; A D Ho; H Goldschmidt; T M Moehler Journal: Int J Hematol Date: 2008-03-04 Impact factor: 2.490
Authors: Mariasanta Napolitano; Giorgia Saccullo; Marco Marietta; Monica Carpenedo; Giancarlo Castaman; Elisabetta Cerchiara; Antonio Chistolini; Laura Contino; Valerio De Stefano; Anna Falanga; Augusto B Federici; Elena Rossi; Rita Santoro; Sergio Siragusa; Valerio De Stefano; Anna Falanga; Alberto Tosetto; Giuseppe Avvisati; Monica Carpenedo; Augusto B Federici; Marco Marietta; Mariasanta Napolitano; Elena Rossi; Cristina Santoro; Giancarlo Castaman; Elisabetta Cerchiara; Antonio Chistolini; Laura Contino; Maria Gabriella Mazzucconi; Ilaria Nichele; Laura Russo; Roberto Santi; Rita Carlotta Santoro; Sergio Siragusa; Giuseppe Tagariello Journal: Blood Transfus Date: 2018-10-24 Impact factor: 3.443
Authors: Giulia Mastrorilli; Francesca Fiorentino; Carmen Tucci; Gloria Lombardi; Alessio Aghemo; Giorgio L Colombo Journal: Clinicoecon Outcomes Res Date: 2022-04-08